Sex: F
Vaccine: RAB
Symptoms: Immunoglobulin therapy, Product administered at inappropriate site
Clinical narrative: RabAvert vaccine administered in gluteal muscle; Case reference number US-BN-2022-002190 is a spontaneous case report initially received on 31-Aug-2022 from a consumer via Communications (reference number: USBAV22-1240) and concerns a 25-year-old female patient.  The patient's medical history and concomitant medication details were not provided.  On 27-Aug-2022, the patient was exposed to a rabid bat and was vaccinated with the first dose of RabAvert (rabies virus (inactivated, strain flury LEP) (PCEC); batch number: unknown), at an unknown dose, administered intramuscularly, in the gluteal muscle, for rabies exposure (explicitly coded as 'vaccine administered at inappropriate site'). The patient also received two shots in the arm, which were more fluid and smaller, and the reporter believed it was immunoglobulin, as reported.  On 30-Aug-2022, three days after the first dose, the patient was vaccinated with the second dose of RabAvert (batch number: unknown) at an unknown dose, administered intramuscularly, in the arm.  At the time of this report, it was unknown if patient experienced any adverse events.  Additional information received on 31-Aug-2022 included the local case ID.; Reporter's Comments: A 25-year-old female patient was exposed to a rabid bat and was vaccinated with the first dose of RabAvert, at an unknown dose, administered intramuscularly, in the gluteal muscle, for rabies exposure which is considered as vaccine administered at inappropriate site. Reportedly, the patient also received two shots in the arm, which were more fluid and smaller, and the reporter believed it was immunoglobulin. Three days after the first dose, the patient was vaccinated with the second dose of RabAvert, at an unknown dose, administered intramuscularly, in the arm. Product administered at inappropriate site is considered listed per company convention. At this point, it was unknown if patient experienced any adverse events due to RabAvert. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 25-year-old female patient was exposed to a rabid bat and was vaccinated with the first dose of RabAvert, at an unknown dose, administered intramuscularly, in the gluteal muscle, for rabies exposure which is considered as vaccine administered at inappropriate site. Reportedly, the patient also received two shots in the arm, which were more fluid and smaller, and the reporter believed it was immunoglobulin. Three days after the first dose, the patient was vaccinated with the second dose of RabAvert, at an unknown dose, administered intramuscularly, in the arm. Product administered at inappropriate site is considered listed per company convention. At this point, it was unknown if patient experienced any adverse events due to RabAvert. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.